A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness.

A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness.
复制标题

DOI:
10.1080/00952990.2021.1946071
复制
发表时间:
2021-09-03
影响因子:
2.7
通讯作者:
George, Tony P.
George, Tony P.
中科院分区:
医学3区
文献类型:
--
作者:
Kozak, Karolina;Smith, Philip H.;Lowe, Darby J. E.;Weinberger, Andrea H.;Cooper, Ziva D.;Rabin, Rachel A.;George, Tony P.

文献摘要

参考文献

被引文献

相似文献

While males are more likely diagnosed with cannabis use disorder (CUD), females are more susceptible to developing and maintaining CUD. Yet, for both sexes, CUD is associated with high rates of comorbid mental illness (MI). To identify and compare sex differences in the prevalence of comorbid CUD amongst individuals with/without MIs. This systematic review generated pooled odds ratios (OR) and 95% confidence intervals (CI) from 37 studies (including clinical trials, cohort, and case-control studies) among individuals with and without MIs, quantifying sex differences in rates of comorbid CUD. A meta-analysis was also completed. In the CUD-only group, males were twice as likely to have CUD than females (OR = 2.0, CI = 1.9–2.1). Among MIs, males were more likely than females to have CUD comorbid with schizophrenia (OR ~2.6, CI = 2.5–27) and other psychotic, mood, and substance use disorders (1 > OR <2.2, CI = 0.7–2.6). The reverse association (females > males) was observed for anxiety disorders and antisocial personality disorder (OR = 0.8, CI = 0.7–1.0). Among females. MIs increased the likelihood of having CUD, except for psychotic disorders and depression. A meta-analysis was inconclusive due to high heterogeneity across studies. Thus, comparisons across MI groups were not possible. While males are more likely to be diagnosed with CUD, there are important sex differences in the prevalence of CUD across MI diagnoses that should be taken into account when approaching CUD prevention and determining treatment efficacy.
DOI: 10.1186/1471-244x-13-82
发表时间: 2013-03-13
期刊: BMC psychiatry
影响因子: 4.4
作者:
Cotton SM;Lambert M;Berk M;Schimmelmann BG;Butselaar FJ;McGorry PD;Conus P
通讯作者: Conus P
DOI: 10.1016/j.addbeh.2015.05.014
发表时间: 2015-10
影响因子: 4.4
作者:
Crane, Natania A.;Langenecker, Scott A.;Mermelstein, Robin J.
通讯作者: Mermelstein, Robin J.
DOI: 10.1176/appi.ajp.2009.09010105
发表时间: 2010-06-01
影响因子: 17.7
作者:
Altshuler, Lori L.;Kupka, Ralph W.;Zermeno, Melanie
通讯作者: Zermeno, Melanie
DOI: 10.1016/j.psychres.2012.05.025
发表时间: 2012-12-30
影响因子: 11.3
作者:
Braga, Raphael J.;Burdick, Katherine E.;Malhotra, Anil K.
通讯作者: Malhotra, Anil K.
DOI: 10.1016/j.drugalcdep.2019.05.008
发表时间: 2019-11-01
影响因子: 4.2
作者:
Compton, Wilson M.;Han, Beth;Blanco, Carlos
通讯作者: Blanco, Carlos